SK Life Science Set New Growth Strategy in Chicago
The company gathered over 160 sales staff to align plans for expanding cenobamate across new patient populations.
Updated on Oct. 2, 2026 in Remote Work
Live Poll
Do you trust that pharmaceutical companies prioritize patient health when expanding uses for their existing drugs?
SK Life Science held its 2026 Plan of Action meeting in Chicago from September 29 to October 1 to review first-half performance and prepare for upcoming product commercialization. The event focused on accelerating growth for the company's drug cenobamate.
Why it matters
The firm is shifting its market strategy by diversifying its cenobamate formulation and expanding into pediatric and adolescent patient groups. This approach aims to secure new revenue streams by targeting broader seizure classifications.
More than 160 sales staff convened to execute the company's One Team strategy. This group is tasked with managing the expansion of cenobamate indications and the rollout of new product formulations.
The players
SK Life Science
A pharmaceutical subsidiary focused on the development and commercialization of treatments for central nervous system disorders.
The details
The company is transitioning its operational focus to include pediatric and adolescent patients alongside its existing market. By developing an oral suspension formulation, the firm intends to improve administration flexibility. This aligns with a One Team structure designed to synchronize headquarters and U.S. subsidiary operations during product commercialization phases.
Timeline
The National Sales Meeting was held in February 2026.
The 2026 Plan of Action meeting occurred from September 29 to October 1, 2026.
Market Landscape
The firm is scaling its market presence by building on the established clinical utility of cenobamate. This move follows a typical industry progression of diversifying drug delivery methods to capture untapped pediatric and adolescent demographic segments.
Operators should monitor how the company synchronizes its headquarters and U.S. subsidiary teams during the rollout of new formulations. The success of this One Team strategy will hinge on the firm's ability to navigate regulatory requirements for the new patient indications.
The takeaway
The firm is prioritizing vertical growth by adding new delivery mechanisms and patient demographics to its existing portfolio. Leaders should track the firm's ability to maintain a unified strategy while scaling across these diverse medical segments.
Further reading
For more updates on how regional teams are managing distributed operations, visit our Remote Work section.
Source note: This article includes information reported by Business Korea.
Live Poll
Do you trust that pharmaceutical companies prioritize patient health when expanding uses for their existing drugs?
